Imlunestrant is a next-generation, brain-penetrant, oral SERD. The EMBER-3 trial in patients with ER+, HER2- ABC and disease progression on/after an aromatase inhibitor (AI) therapy ± CDK4/6 inhibitor (CDK4/6i) showed significant PFS improvement with imlunestrant over standard therapy (SOC) among patients with ESR1 mutations (ESR1m), and with imlunestrant+abemaciclib over imlunestrant in all patients regardless of ESR1m status. An exploratory analysis of efficacy by line-of-therapy is presented here.
Subgroup analyses of PFS were performed by line-of-therapy for imlunestrant (400mg once daily) vs SOC (fulvestrant/exemestane per label) in patients with ESR1m, and imlunestrant (400mg once daily) + abemaciclib (150mg BID) vs imlunestrant and vs SOC in all concurrently randomized patients. Eligible patients included 1L patients with ABC who experienced recurrence on/within 12 months from completion of AI±CDK4/6i as (neo)adjuvant treatment, and 2L patients who progressed on 1L treatment for ABC.
Overall, 33% patients received study therapy as 1L for ABC and 67% as 2L treatment. Among patients with ESR1m across imlunestrant and SOC arms, 21% were treated in the 1L setting (79% 2L). Among all patients, ESR1m were less frequent in 1Lvs2L (24%vs43%), as were incidences of prior CDK4/6i treatment (12%vs83%). Consistent PFS benefit was observed for imlunestrant vs SOC in patients with ESR1m (1L HR=0.48[95%CI:0.25,0.92], 2L HR=0.66[95%CI:0.48,0.90]), and imlunestrant+abemaciclib vs imlunestrant (1L HR=0.55 [95%CI:0.34,0.90], 2L HR=0.62 [95%CI:0.47,0.83]) and vs SOC (1L HR=0.44 [95%CI:0.27,0.71], 2L HR=0.51 [95%CI:0.39,0.68]) in all patients, regardless of line-of-treatment. A numerically longer PFS was observed in 1L patients (imlunestrant+abemaciclib: 14.4 [7.6,NR] vs 9.1 months [7.4,11.1], imlunestrant: 11.1 [4.7,11.1] vs 5.5 months [3.7,5.7], SOC: 5.7 [3.7,8.7] vs 3.8 months [3.7,5.5]).
Consistent with the primary EMBER-3 analyses, a benefit in PFS was observed across 1L and 2L subgroups. Imlunestrant alone or with abemaciclib, provides an all-oral targeted therapy option in the 1L or 2L setting for patients with endocrine therapy-resistant ER+, HER2- ABC.